Two new mAbs, alirocumab and
evolocumab, have been approved to treat elevated cholesterol when
added to maximally tolerated statin therapy in patients with familial
hypercholesterolemia or history of atherosclerotic cardiovascular disease
(ASCVD). This new class of drugs, the proprotein convertase subtilisin/kexin
type 9 (PCSK9) inhibitors, is considered to be the biggest breakthrough in
cholesterol treatment since statins were approved 3 decades ago. But are they
worth it?
view more